Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies - GBI Research Reports

Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies

Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies - GBI Research Reports
Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies
Published Nov 30, 2013
80 pages — Published Nov 30, 2013
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its pharma research, 'Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies', which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.

Scope

- Disease overview and treatment usage patterns
- Market size and forecast for glaucoma and DES in Top Eight Markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) from 2012 to 2019
- Major marketed products for the indications types covered
- In-depth pipeline analysis for glaucoma and DES
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements in the ophthalmology market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

  
Source:
Document ID
GBIHC317MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents64
  List of Tables81
  List of Figures91
Ophthalmology Therapeutics in Major Markets Introduction1011
  Dry Eye Syndrome101
    Classification101
    Symptoms101
    Etiology101
    Pathophysiology111
    Diagnosis121
    Epidemiology131
    Prognosis141
    Treatment Options141
  Glaucoma151
    Classification151
    Symptoms161
    Etiology161
    Pathophysiology171
    Diagnosis171
      Tonometry171
      Pachymetry181
      Gonioscopy181
      Ophthalmoscopy181
      Visual Field Testing181
    Epidemiology181
    Prognosis191
    Treatment Options191
      Pharmacological Treatment191
      Laser Surgery201
      Traditional Surgery201
Ophthalmology Therapeutics in Major Markets Marketed Products (Global)219
  Dry Eye Syndrome211
  Glaucoma211
  Key Marketed Products221
    Restasis221
    Systane231
    Diquas241
    Mucosta251
    Hyalein261
    Lumigan271
    Alphagan/Alphagan P281
    Simbrinza291
Ophthalmology Therapeutics in Major Markets Pipeline Analysis3013
  Dry Eye Syndrome Pipeline301
    Overall Pipeline302
    Pipeline Analysis by Molecule Type322
    Pipeline Analysis by Mechanism of Action342
  Glaucoma Pipeline361
    Overall Pipeline362
    Pipeline Analysis by Molecule Type381
    Pipeline Analysis by Mechanism of Action392
  Promising Drug Candidates in the Pipeline411
    CF-101411
    MIM-D3411
    SAR-1118411
    DE-111421
Ophthalmology Therapeutics in Major Markets Market Forecast to 20194312
  Major Markets431
    Treatment Usage Patterns431
    Annual Cost of Therapy431
    Market Size432
  The US451
    Treatment Usage Patterns451
    Annual Cost of Therapy451
    Market Size452
  Top Five European Countries471
    Treatment Usage Patterns471
    Annual Cost of Therapy471
    Market Size472
  Canada491
    Treatment Usage Patterns491
    Annual Cost of Therapy491
    Market Size492
  Japan511
    Treatment Usage Patterns511
    Annual Cost of Therapy511
    Market Size512
  Drivers and Barriers531
    Drivers531
      Increase in Prevalence of Dry Eye Syndrome531
      Launch of New Prescription Products531
    Barriers531
      Lack of Awareness and Compliance531
      Patent Expiries of Major Marketed Drugs532
Ophthalmology Therapeutics in Major Markets Deals and Strategic Consolidations (Global)556
  Deals Analysis552
  Major Co-Development Deals571
    NicOx Signs Research Agreement with Pfizer581
    Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide581
    Akorn Enters into Agreement with Azad Pharma581
  Major Licensing Deals591
    NicOx Enters into Worldwide Licensing Agreement with Bausch &Lomb601
    Quark Pharma Amends Licensing Agreement with Pfizer for PF-655601
    Asterand Enters into Licensing Agreement with Allergan601
Ophthalmology Therapeutics in Major Markets Appendix6120
  All Pipeline Drugs by Phase616
    Discovery611
    Preclinical612
    IND/CTA-filed631
    Phase I631
    Phase II641
    Phase III651
    Pre-registration651
    Undisclosed661
  Market Forecasts to 2019667
    Major Markets661
      Dry Eye Syndrome661
      Glaucoma661
    The US671
      Dry Eye Syndrome671
      Glaucoma671
    The UK671
      Dry Eye Syndrome671
      Glaucoma681
    France681
      Dry Eye Syndrome681
      Glaucoma681
    Germany691
      Dry Eye Syndrome691
      Glaucoma691
    Italy691
      Dry Eye Syndrome691
      Glaucoma701
    Spain701
      Dry Eye Syndrome701
      Glaucoma701
    Canada711
      Dry Eye Syndrome711
      Glaucoma711
    Japan711
      Dry Eye Syndrome711
      Glaucoma721
  Market Definitions721
  Abbreviations722
  Sources741
  Research Methodology756
    Coverage761
    Secondary Research761
    Primary Research761
    Therapeutic Landscape772
      Market Size by Geography791
    Geographical Landscape801
    Pipeline Analysis801
  Expert Panel Validation801
  Contact Us801
  Disclaimer801

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies" Nov 30, 2013. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Ophthalmology-Therapeutics-in-Major-Developed-Markets-to-2019-New-Drug-Approvals-and-Promising-Pipeline-to-Trigger-Shift-in-Treatment-Paradigm-to-Combination-Therapies-2115-623>
  
APA:
GBI Research Reports. (2013). Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies Nov 30, 2013. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Ophthalmology-Therapeutics-in-Major-Developed-Markets-to-2019-New-Drug-Approvals-and-Promising-Pipeline-to-Trigger-Shift-in-Treatment-Paradigm-to-Combination-Therapies-2115-623>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.